Markets
Joe Biden debate
(Andrew Caballero Reynolds/Getty Images)

The markets saw the debate too

Here’s their verdict.

It’s always a bit dangerous to try to ascribe specific reasons for any particular market move. But it seems pretty obvious that the shockwaves from Thursday’s US presidential debate are emanating through financial markets on Friday.

Popular opinion suggests that the debate had a decisive winner: Donald Trump.

Just look at how Goldman Sachs’ themed basket of stocks that should do well under a Trump administration is doing today compared to a similar basket of stocks that should benefit from a Democratic White House. It’s outperforming by more than 3 percentage points, the most this year.

On PredictIt, the odds of Trump winning the 2024 presidential election rose from 54% before the debate to as high as 64% during the event.

“President Biden and his team now have much more work to do to win re-election than Trump,” writes Kim Wallace, head of Washington Policy Research at 22V Research. “Biden flubbed softball opportunities from questioners and Trump, shocking Democrats and likely many non-Democrats as well.”

Here’s some of what we’re seeing in markets.

Solar sell-off

The most glaring stock-market reaction seems to be in shares of companies that would benefit from policies associated with Democratic priorities. Solar firms like Maxeon Solar Technologies, Sunnova Energy and First Solarare getting creamed as traders seem to be pricing in higher odds of Trump 2.0.

End of Obamacare?

Likewise, health-insurance companies that’ve built large businesses around the Affordable Care Act’s insurance plan exchanges are also suffering Friday. Oscar Health, HCA Healthcare and Tenet Healthcareare all taking it on the chin.

Prisons, private education, and coal companies romp

Conversely, companies investors think will do well under a Republican administration surged on Friday; foremost among them were private prison companies GEO Group, and CoreCivic (formerly Corrections Corporation of America), as well as private education firms such as Grand Canyon Education, and private college operator Laureate Education. Finally, coal companies Peabody Energy and Arch Resources had very good days, as some price in roll backs of climate-related Biden administration initiatives.

GSE reform back on the agenda

During his term, Trump backed attempts to privatize the government-sponsored entities Fannie Mae and Freddie Mac. Shares of both are up roughly double digits on Friday.

RIP, Fed independence?

Perhaps the most notable reaction of the day isn’t in the stock market, but rather in the market for US Treasury bonds. Despite really good news on the inflation front — the Fed’s key measure of inflation dropped more than expected to its lowest level since March 2021 — longer-term Treasury bonds tumbled, pushing yields, which move in the opposite direction, sharply higher.

Since long-term bonds typically rise when inflation comes down, this is a bit odd. It seems, at least to me, that some people are pricing in the long-term effect of a second Trump term on the “full faith and credit” of the United States.

Trump allies’ reported plans to fiddle with the Fed’s traditional independence from direct political control would explain some of that move. Efforts, typically by quasi-or-outright dictatorial governments, to control monetary policy usually works out horribly both for investors in those country’s bonds and for the country itself, as surges of serious inflation — see Turkish, Hungarian or Russian inflation rates in recent years — follows from printing money for political reasons.

Of course there are varying explanations for the move in US Treasury yields. The inflation data, though positive, was well telegraphed before its release and in line with economists’ expectations.

And the market could also be pricing in the potential for better growth thanks to more fiscal stimulus in the event of a united Republican government, or higher inflation because of Trump’s tariffs.

Speaking of Russia

One can’t help notice that the ruble — which really isn’t traded on markets much anymore — and Russian stocks were up slightly on the day. Hard to say why, though Trump’s friendliness toward the Kremlin could translate into easing the sanctions the world imposed on Russia for invading and occupying eastern Ukraine, or a potential end to the conflict — as Trump promised would happen if he wins the election, even before his term begins.

Currency confusion

But of course not everything in markets can be perfectly congruent. The most common Wall Street prognostication is that a Trump presidency would lead to a stronger US dollar (primarily because of the risk of tariffs). But the greenback is slightly lower on the day, as judged by the Dollar Spot Index, and lower against every G10 currency besides the Norwegian krone.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.